Purple Biotech (PPBT) Liabilities and Shareholders Equity (2014 - 2026)

Purple Biotech (PPBT) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $14.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 59.5% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $105.4 million (down 26.69% YoY), while the FY2025 annual figure was $17.6 million, down 52.56% from the prior year.
• Liabilities and Shareholders Equity retreated to $14.4 million in Q1 2026 per PPBT's latest filing, from $17.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $66.3 million in Q1 2022 and bottomed at $14.4 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $42.4 million across 5 years, with a median of $39.9 million in 2024.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity gained 11.27% — and 2026, when it tumbled 59.5%.
• Purple Biotech's Liabilities and Shareholders Equity stood at $54.6 million in 2022, then decreased by 18.89% to $44.3 million in 2023, then retreated by 16.4% to $37.0 million in 2024, then slumped by 52.56% to $17.6 million in 2025, then fell by 17.95% to $14.4 million in 2026.
• Business Quant data shows PPBT's Liabilities and Shareholders Equity at $14.4 million in Q1 2026, $17.6 million in Q4 2025, and $39.1 million in Q3 2025.